I listened to Steve Davis of Acadia during the 3rd Annual Novel...

I listened to Steve Davis of Acadia during the 3rd Annual Novel Mechanism in Neuropsychiatry Summit held on September 20 at TD Cowen. My notes show that Steve advised that is the suit with MSN was successful, patent life for Nuplazid for the treatment of Parkinson’s Disease psychosis would extend through October 2030, and if not successful, would extend through January 2028. Steve said that the Pimvanserin franchise for PDP now produces ~ US $ 300 million in free cash flow. So a loss to MSN in litigation would translates into loss for Acadia of 33 months of free cash flow on PDP or ~ US $ 825 million, which would hurt. Can’t tell who is winning or won the MSN litigation but the market is reacting as if Acadia lost.